Skip Navigation

Neuro-Oncology 2009 11(3):301-310; doi:10.1215/15228517-2008-088
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zhou, Q.
Right arrow Articles by Gallo, J. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zhou, Q.
Right arrow Articles by Gallo, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

Qingyu Zhou and James M. Gallo

Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, PA, USA

Address correspondence to James M. Gallo, Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, 3307 North Broad St., Philadelphia, PA 19140, USA (jmgallo{at}temple.edu).


  Abstract

Normalization of tumor vasculature by antiangiogenic agents may improve the delivery of cytotoxic drugs to the tumor, leading to more effective therapy. In this study, we used pharmacokinetic and pharmacodynamic approaches to investigate how sunitinib at different dose levels affects brain distribution of temozolomide (TMZ), and to ascertain the relationship between intratumoral TMZ concentrations and tumor vascularity in an orthotopic human glioma model. Three groups of intracerebral U87MG tumor-bearing mice were given either vehicle or sunitinib at 20 mg/kg or 60 mg/kg per day for 7 days before receiving a steady-state regimen of TMZ that consisted of an intravenous bolus and a 3-h intraarterial infusion. TMZ concentrations in plasma, normal brain, and brain tumor were determined, and several biomarkers related to the antiangiogenic activity of sunitinib were examined. TMZ distribution in the normal brain as indicated by the brain-to-plasma steady-state TMZ concentration ratios was analogous across the three treatment groups. The brain tumor-to-plasma steady-state TMZ concentration (ss Ct/Cp) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 ± 0.17) compared with the control (0.76 ± 0.17) and 60 mg/kg sunitinib (0.68 ± 0.09) groups. The ss Ct/Cp ratios were significantly correlated with the vascular normalization index (VNI), derived from the expression of CD31, collagen IV, and {alpha}-smooth muscle actin, which represents the fraction of functioning vessels out of the total tumor vessels. In conclusion, the effect of sunitinib on the brain tumor distribution of TMZ was dose dependent and indicated that optimal tumor exposure was achieved at a lower dose and was associated with the VNI.

Keywords: antiangiogenic therapy, combination chemotherapy, pharmacokinetics, sunitinib, temozolomide, vascular normalization

Received May 20, 2008; Accepted October 10, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.